{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:55:22Z","timestamp":1776056122906,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Compounding drug products is a vital hospital pharmacy feature that requires safe and compatible primary packaging, particularly for prefilled syringes (PFSs). The off-label use of plastic syringes in batch compounding for intravitreal administration has raised concerns over leachables and silicone oil lubricants, which may migrate into drug solutions and potentially cause toxicity. This study evaluated two widely used off-label plastic syringes, BD Plastipak and BBraun Omnifix, for conditioning with topotecan (TPT), a chemotherapeutic used to treat infant retinoblastoma. Leachables were monitored over 12 months via an original LC\u2012MS method with postcolumn infusion (PCI), including possible detection of silicone degradants. This approach may serve as an indirect method to assess silicone-related contamination due to the spread of free silicone particulates. Both syringes released low overall levels of leachables. However, BD Plastipak emits five oligomeric degradants, two exceeding permitted daily exposure (PDE) limits. In contrast, BBraun Omnifix showed greater chemical stability, releasing only minimal silicone-related compounds and oleamide, suggesting a lower risk for intraocular use. Although these findings support BBraun Omnifix as a safer option, the findings underscore the need for toxicologically assessed, purpose-designed plastic PFSs made from low-extractable materials such as cyclic olefin polymer (COP) or copolymer (COC) for long-term drug storage.<\/jats:p>","DOI":"10.1038\/s41598-025-24557-9","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:08:50Z","timestamp":1763554130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of leachables in hospital pharmacy compounded topotecan conditioned in common off-label syringes for intravitreal use"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8704-130X","authenticated-orcid":false,"given":"William","family":"Bello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6680-0062","authenticated-orcid":false,"given":"Camille","family":"Hosotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-0790","authenticated-orcid":false,"given":"Camille","family":"Stampfli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7937-611X","authenticated-orcid":false,"given":"Antoine","family":"Pierrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-1050","authenticated-orcid":false,"given":"Francis L.","family":"Munier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1833-9616","authenticated-orcid":false,"given":"Markoulina","family":"Berger-Gryllaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-8128","authenticated-orcid":false,"given":"Laurent","family":"Carrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-8240","authenticated-orcid":false,"given":"Julian","family":"Pezzatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0817-5393","authenticated-orcid":false,"given":"Farshid","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"24557_CR1","doi-asserted-by":"publisher","unstructured":"Ortiz, M. V. & Dunkel, I. J.   Retinoblastoma. J. Child. Neurol. 31 (2), 227\u2013236. https:\/\/doi.org\/10.1177\/0883073815587943  (2016).","DOI":"10.1177\/0883073815587943"},{"key":"24557_CR2","doi-asserted-by":"publisher","unstructured":"Munier, F. L. et al. Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace. Alive, with good vision and no comorbidity. Prog. Retin Eye Res. 73, 2563.  https:\/\/doi.org\/10.1016\/j.preteyeres.2019.05.005 (2019).","DOI":"10.1016\/j.preteyeres.2019.05.005"},{"issue":"11","key":"24557_CR3","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","volume":"68","author":"D Ancona-Lezama","year":"2020","unstructured":"Ancona-Lezama, D., Dalvin, L. A. & Shields, C. L. Modern treatment of retinoblastoma: a 2020 review. Indian J. Ophthalmol. 68 (11), 2356\u20132365. https:\/\/doi.org\/10.4103\/ijo.IJO_721_20 (2020).","journal-title":"Indian J. Ophthalmol."},{"issue":"4","key":"24557_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/13816810.2020.1776336","volume":"41","author":"F Bossacoma","year":"2020","unstructured":"Bossacoma, F. et al. Optimizing the storage of chemotherapeutics for ophthalmic oncology: stability of Topotecan solution for intravitreal injection. Ophthalmic Genet. 41 (4), 397\u2013400. https:\/\/doi.org\/10.1080\/13816810.2020.1776336 (2020).","journal-title":"Ophthalmic Genet."},{"key":"24557_CR5","doi-asserted-by":"publisher","first-page":"109026","DOI":"10.1016\/j.exer.2022.109026","volume":"218","author":"MJ Del Sole","year":"2022","unstructured":"Del Sole, M. J. et al. Ocular and systemic toxicity of high-dose intravitreal Topotecan in rabbits: implications for retinoblastoma treatment. Exp. Eye Res. 218, 109026. https:\/\/doi.org\/10.1016\/j.exer.2022.109026 (2022).","journal-title":"Exp. Eye Res."},{"key":"24557_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.exer.2013.01.002","volume":"108","author":"E Buitrago","year":"2013","unstructured":"Buitrago, E. et al. Ocular and systemic toxicity of intravitreal Topotecan in rabbits for potential treatment of retinoblastoma. Exp. Eye Res. 108, 103\u2013109. https:\/\/doi.org\/10.1016\/j.exer.2013.01.002 (2013).","journal-title":"Exp. Eye Res."},{"issue":"7","key":"24557_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/bjophthalmol-2020-316588","volume":"105","author":"JF Nadelmann","year":"2021","unstructured":"Nadelmann, J. F., Brodie, J. H., Muca, S. E. & Abramson, E. Is intravitreal Topotecan toxic to retinal function? Br. J. Ophthalmol. 105 (7), 1016\u20131018. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316588 (2021).","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"24557_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10384-020-00743-2","volume":"64","author":"H Kiratli","year":"2020","unstructured":"Kiratli, H., Koc, I., Ozturk, E., Varan, A. & Akyuz, C. Comparison of intravitreal Melphalan with and without Topotecan in the management of vitreous disease in retinoblastoma. Jpn J. Ophthalmol. 64 (4), 351\u2013358. https:\/\/doi.org\/10.1007\/s10384-020-00743-2 (2020).","journal-title":"Jpn J. Ophthalmol."},{"key":"24557_CR9","doi-asserted-by":"publisher","first-page":"696787","DOI":"10.3389\/fphar.2021.696787","volume":"12","author":"YA Yousef","year":"2021","unstructured":"Yousef, Y. A. et al. Safety and efficacy of intravitreal chemotherapy (Melphalan) to treat vitreous seeds in retinoblastoma. Front. Pharmacol. 12, 696787. https:\/\/doi.org\/10.3389\/fphar.2021.696787 (2021).","journal-title":"Front. Pharmacol."},{"key":"24557_CR10","doi-asserted-by":"publisher","unstructured":"Bello, W. et al. Stability study of Topotecan in ophthalmic prefilled syringes for intravitreal delivery. Eur. J. Hosp. Pharm. 2025 Jan 20, ejhpharm\u20132024. https:\/\/doi.org\/10.1136\/ejhpharm-2024-004346 (2024).","DOI":"10.1136\/ejhpharm-2024-004346"},{"key":"24557_CR11","doi-asserted-by":"publisher","first-page":"204209862513174","DOI":"10.1177\/20420986251317424","volume":"16","author":"W Bello","year":"2025","unstructured":"Bello, W. et al. A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging. Ther. Adv. Drug Saf. 16, 20420986251317424. https:\/\/doi.org\/10.1177\/20420986251317424 (2025).","journal-title":"Ther. Adv. Drug Saf."},{"key":"24557_CR12","unstructured":"PIC\/S Guide to Good Practices for the Preparation of Medicinal Products in Healthcare Establishments (PE 010\u20134). Pharmaceutical Inspection Co\u2013operation Scheme  (2014)."},{"issue":"8","key":"24557_CR13","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.xphs.2024.05.012","volume":"113","author":"D Mule","year":"2024","unstructured":"Mule, D. et al. Drug-Leachable interaction product evaluation in prefilled syringe of Ganirelix acetate injection. J. Pharm. Sci. 113 (8), 2023\u20132027. https:\/\/doi.org\/10.1016\/j.xphs.2024.05.012 (2024).","journal-title":"J. Pharm. Sci."},{"key":"24557_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40942-021-00338-0","volume":"7","author":"GB Melo","year":"2021","unstructured":"Melo, G. B., Shoenfeld, Y. & Rodrigues, E. B. The risks behind the widespread use of siliconized syringes in the healthcare practice. Int. J. Retin Vitr. 7, 66. https:\/\/doi.org\/10.1186\/s40942-021-00338-0 (2021).","journal-title":"Int. J. Retin Vitr"},{"key":"24557_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-018-0153-8","volume":"5","author":"GB Melo","year":"2019","unstructured":"Melo, G. B. et al. Release of silicone oil droplets from syringes. Int. J. Retin Vitr. 5, 1. https:\/\/doi.org\/10.1186\/s40942-018-0153-8 (2019).","journal-title":"Int. J. Retin Vitr"},{"issue":"9","key":"24557_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamaophthalmol.2023.3495","volume":"141","author":"J Bijon","year":"2023","unstructured":"Bijon, J., Mundae, R., Fisher, Y. & Freund, K. B. Multiple small floaters associated with silicone oil droplets following intravitreal Pegcetacoplan injection. JAMA Ophthalmol. 141 (9), 907\u2013909. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.3495 (2023).","journal-title":"JAMA Ophthalmol."},{"key":"24557_CR17","doi-asserted-by":"publisher","first-page":"115640","DOI":"10.1016\/j.jpba.2023.115640","volume":"236","author":"W Bello","year":"2023","unstructured":"Bello, W., Pezzatti, J., Berger-Gryllaki, M., Rudaz, S. & Sadeghipour, F. Development of a generic approach for monitoring leachable compounds in hospital pharmacy-prepared prefilled plastic packaging by ultrahigh-performance liquid chromatography coupled to high-resolution mass spectrometry with postcolumn infusion. J. Pharm. Biomed. Anal. 236, 115640. https:\/\/doi.org\/10.1016\/j.jpba.2023.115640 (2023).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"24557_CR18","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1016\/j.xphs.2024.08.004","volume":"113","author":"W Bello","year":"2024","unstructured":"Bello, W., Pezzatti, J., Rudaz, S. & Sadeghipour, F. Study of leachable compounds in hospital pharmacy-compounded prefilled syringes, infusion bags and vials. J. Pharm. Sci. 113 (11), 3227\u20133237. https:\/\/doi.org\/10.1016\/j.xphs.2024.08.004 (2024).","journal-title":"J. Pharm. Sci."},{"key":"24557_CR19","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q3E: Concept paper for the development of a guideline for extractables and leachables  (2020).  https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q3E_ConceptPaper_2020_0710.pdf."},{"key":"24557_CR20","doi-asserted-by":"publisher","unstructured":"Jenke, D. et al. Evaluation of the general solution compatibility of polymer materials used in medical devices such as syringes. PDA J. Pharm. Sci. Technol. 66 (4), 286\u2013306. https:\/\/doi.org\/10.5731\/pdajpst.2012.00869 (2012).","DOI":"10.5731\/pdajpst.2012.00869"},{"key":"24557_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jhazmat.2017.10.014","volume":"344","author":"JN Hahladakis","year":"2018","unstructured":"Hahladakis, J. N., Velis, C. A., Weber, R., Iacovidou, E. & Purnell, P. An overview of chemical additives present in plastics: migration, release, fate and environmental impact during their use, disposal and recycling. J. Hazard. Mater. 344, 179\u2013199. https:\/\/doi.org\/10.1016\/j.jhazmat.2017.10.014 (2018).","journal-title":"J. Hazard. Mater."},{"issue":"4","key":"24557_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/2230-973X.93004","volume":"1","author":"S Makwana","year":"2011","unstructured":"Makwana, S., Basu, B., Makasana, Y. & Dharamsi, A. Prefilled syringes: an innovation in parenteral packaging. Int. J. Pharm. Investig. 1 (4), 200\u2013206. https:\/\/doi.org\/10.4103\/2230-973X.93004 (2011).","journal-title":"Int. J. Pharm. Investig"},{"key":"24557_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jcis.2017.06.040","volume":"505","author":"N Dulal","year":"2017","unstructured":"Dulal, N. et al. Slip-additive migration, surface morphology, and performance on injection moulded high-density polyethylene closures. J. Colloid Interface Sci. 505, 537\u2013545. https:\/\/doi.org\/10.1016\/j.jcis.2017.06.040 (2017).","journal-title":"J. Colloid Interface Sci."},{"key":"24557_CR24","doi-asserted-by":"crossref","unstructured":"Bishop, C. A. Vacuum Deposition Onto Webs, Films and Foils  149  (William Andrew, 2015).","DOI":"10.1016\/B978-0-323-29644-1.00008-6"},{"key":"24557_CR25","unstructured":"International Council for Harmonisation (ICH). ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A(R2) (ICH Secretariat, 2003)."},{"issue":"11","key":"24557_CR26","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1039\/d3ay02234j","volume":"16","author":"W Bello","year":"2024","unstructured":"Bello, W., Pezzatti, J., Rudaz, S. & Sadeghipour, F. Development of a generic sample Preparation method using dispersive liquid-liquid Microextraction for the monitoring of leachable compounds in hospital pharmacy-prepared prefilled drug products. Anal. Methods. 16 (11), 1697\u20131707. https:\/\/doi.org\/10.1039\/d3ay02234j (2024).","journal-title":"Anal. Methods"},{"key":"24557_CR27","doi-asserted-by":"publisher","unstructured":"Christiaens, P., Beusen, J. M., Verlinde, P., Baeten, J. & Jenke, D. Identifying and mitigating errors in screening for organic extractables and leachables: part 2-Errors of inexact identification and inaccurate quantitation. PDA J. Pharm. Sci. Technol. 74 (1), 108\u2013133. https:\/\/doi.org\/10.5731\/pdajpst.2018.009779 (2020).","DOI":"10.5731\/pdajpst.2018.009779"},{"key":"24557_CR28","doi-asserted-by":"crossref","unstructured":"Ball, D. J. & Beierschmitt, W. P. Permitted daily exposure values: application considerations in toxicological risk assessments. Int. J. Toxicol. 39 (6), 577\u2013585 (2020).","DOI":"10.1177\/1091581820946746"},{"key":"24557_CR29","doi-asserted-by":"publisher","unstructured":"Jenke, D. & Carlson, T. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems. PDA J. Pharm. Sci. Technol. 2014 Sep-Oct ;68 (5),  407\u2013455. https:\/\/doi.org\/10.5731\/pdajpst.2014.00995 (2024).","DOI":"10.5731\/pdajpst.2014.00995"},{"issue":"3","key":"24557_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.yrtph.2005.05.004","volume":"42","author":"MA Dorato","year":"2005","unstructured":"Dorato, M. A. & Engelhardt, J. A. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul. Toxicol. Pharmacol. 42 (3), 265\u2013274. https:\/\/doi.org\/10.1016\/j.yrtph.2005.05.004 (2005).","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"24557_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/toxsci\/kfm058","volume":"97","author":"D Ball","year":"2007","unstructured":"Ball, D. et al. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Toxicol. Sci. 97 (2), 226\u2013236. https:\/\/doi.org\/10.1093\/toxsci\/kfm058 (2007).","journal-title":"Toxicol. Sci."},{"key":"24557_CR32","unstructured":"Toxicity Estimation Software. Tool (TEST) [Internet] (2024, accessed 25 Mar 2024). https:\/\/www.epa.gov\/comptox-tools\/toxicity-estimation-software-tool-test."},{"issue":"4","key":"24557_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/ejhpharm-2016-001045","volume":"24","author":"M Closset","year":"2017","unstructured":"Closset, M. et al. Does an interaction exist between ketamine hydrochloride and Becton Dickinson syringes? Eur. J. Hosp. Pharm. 24 (4), 230\u2013234. https:\/\/doi.org\/10.1136\/ejhpharm-2016-001045 (2017).","journal-title":"Eur. J. Hosp. Pharm."},{"key":"24557_CR34","doi-asserted-by":"publisher","unstructured":"Garay-Aramburu, G. et al. [Translated article] Consensus on intraocular drug preparations. Farm Hosp.    49 (2), T99-T108.  https:\/\/doi.org\/10.1016\/j.farma.2025.03.004 (2025).","DOI":"10.1016\/j.farma.2025.03.004"},{"key":"24557_CR35","doi-asserted-by":"publisher","unstructured":"Pascual Carrasco, \u00c1., Espadas Garc\u00eda, I., Ram\u00edrez L\u00f3pez, A. & Selva Otaolaurruchi, J. [Translated article] Syringes for intraocular administration: a systematic review. Farm. Hosp.     48 (3), T133-T140.  https:\/\/doi.org\/10.1016\/j.farma.2024.04.011 (2024).","DOI":"10.1016\/j.farma.2024.04.011"},{"key":"24557_CR36","unstructured":"McElhiney, L. F. Introduction to hospital compounding. Int. J. Pharm. Compd. 10 (4), 245\u2013250 (2006)."},{"issue":"2","key":"24557_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2146\/ajhp110654","volume":"70","author":"C Stucki","year":"2013","unstructured":"Stucki, C., Sautter, A. M., Wolff, A., Fleury-Souverain, S. & Bonnabry, P. Accuracy of preparation of i.v. medication syringes for anesthesiology. Am. J. Health Syst. Pharm. 70 (2), 137\u2013142. https:\/\/doi.org\/10.2146\/ajhp110654 (2013).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"24557_CR38","doi-asserted-by":"publisher","first-page":"106590","DOI":"10.1016\/j.ejps.2023.106590","volume":"191","author":"TG van Gelder","year":"2023","unstructured":"van Gelder, T. G. et al. Drug waste of ready-to-administer syringes in the intensive care unit: aseptically prepared syringes versus prefilled sterilized syringes. Eur. J. Pharm. Sci. 191, 106590. https:\/\/doi.org\/10.1016\/j.ejps.2023.106590 (2023).","journal-title":"Eur. J. Pharm. Sci."},{"key":"24557_CR39","doi-asserted-by":"publisher","unstructured":"Vrignaud, S. Resolution CM\/Res(2016)2 and centralised intra venous additive services (CIVAS): challenges and opportunities. Pharmaceut. Technol. Hospital Pharm. 2 (3),  137\u2013142. https:\/\/doi.org\/10.1515\/pthp-2017-0023   (2016).","DOI":"10.1515\/pthp-2017-0023"},{"key":"24557_CR40","unstructured":"European Parliament and Council. Regulation (EU) 2017\/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, and repealing directive 90\/385\/EEC and directive 93\/42\/EEC. Official J. Eur. Union. L117, 1\u2013175 (2017). https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32017R0745."},{"key":"24557_CR41","unstructured":"U.S. Food and Drug Administration. Premarket Notification 510(k) Submissions (2023). https:\/\/www.fda.gov\/medical-devices\/premarket-notification-510k."},{"key":"24557_CR42","doi-asserted-by":"publisher","unstructured":"United States Pharmacopeial Convention. USP\u2009<\u20091663>: assessment of extractables associated with pharmaceutical packaging\/delivery systems. USP\u2013NF https:\/\/doi.org\/10.31003\/USPNF_M7126_03_01 (2024).","DOI":"10.31003\/USPNF_M7126_03_01"},{"key":"24557_CR43","doi-asserted-by":"publisher","unstructured":"United States Pharmacopeial Convention. USP\u2009<\u20091664>: assessment of drug product leachables associated with pharmaceutical packaging\/delivery systems. USP\u2013NF https:\/\/doi.org\/10.31003\/USPNF_M7127_03_01 (2024).","DOI":"10.31003\/USPNF_M7127_03_01"},{"key":"24557_CR44","unstructured":"Product Quality Research Institute. (2006\u20132020). PQRI Leachables and Extractables Working Group Recommendations for Pharmaceutical Drug Products. PQRI (2020)."},{"key":"24557_CR45","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q3E: Concept paper for the development of a guideline for extractables and leachables. Retrieved from ICH website (2020)."},{"key":"24557_CR46","unstructured":"European Medicines Agency. Guideline on Plastic Immediate Packaging Materials (CPMP\/QWP\/4359\/03) (EMA, 2005)."},{"key":"24557_CR47","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some Industrial Chemicals. Lyon (FR): International Agency for Research on Cancer; 2000. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 77.) Di(2-ethylhexyl) adipate.  https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK390864\/ (2000)."},{"key":"24557_CR48","doi-asserted-by":"publisher","first-page":"111620","DOI":"10.1016\/j.ecoenv.2020.111620","volume":"208","author":"A Behairy","year":"2021","unstructured":"Behairy, A., Abd El-Rahman, G. I., Aly, S. S. H., Fahmy, E. M. & Abd-Elhakim, Y. M. Di(2-ethylhexyl) adipate plasticizer triggers hepatic, brain, and cardiac injury in rats: mitigating effect of peganum Harmala oil. Ecotoxicol. Environ. Saf. 208, 111620. https:\/\/doi.org\/10.1016\/j.ecoenv.2020.111620 (2021).","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"4","key":"24557_CR49","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2166\/wst.2013.308","volume":"68","author":"D Ga\u00eblle","year":"2013","unstructured":"Ga\u00eblle, D. et al. Hydrolysis of polydimethylsiloxane fluids in controlled aqueous solutions. Water Sci. Technol. . 68 (4), 813\u2013820. https:\/\/doi.org\/10.2166\/wst.2013.308 (2013).","journal-title":"Water Sci. Technol."},{"issue":"5","key":"24557_CR50","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/foods9050549","volume":"9","author":"K Naumoska","year":"2020","unstructured":"Naumoska, K., Jug, U., Metli\u010dar, V. & Vovk, I. Oleamide, a bioactive compound, unwittingly introduced into the human body through some plastic food\/beverages and medicine containers. Foods 9 (5), 549. https:\/\/doi.org\/10.3390\/foods9050549 (2020).","journal-title":"Foods"},{"issue":"1","key":"24557_CR51","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41598-020-59093-1","volume":"10","author":"U Jug","year":"2020","unstructured":"Jug, U. et al. Interference of oleamide with analytical and bioassay results. Sci. Rep. 10 (1), 2163. https:\/\/doi.org\/10.1038\/s41598-020-59093-1 (2020).","journal-title":"Sci. Rep."},{"key":"24557_CR52","unstructured":"Becton & Dickinson and Company. BD Plastipak\u2122 [Technical Sheet]. Consumables Compliance. (n.d.). Technical Data Sheet No. 100\u20130953 [PDF] (2025). https:\/\/downloads.consumables.com\/doc\/tds\/100-0953_TDS.pdf."},{"key":"24557_CR53","unstructured":"Braun Medical, B. AG. Omnifix F ready-to-fill syringe [Product catalog]  (2025). https:\/\/catalogs.bbraun.ch\/fr-CH\/p\/PRID00000578\/omnifix-f?bomUsage=marketingDocuments."},{"issue":"1","key":"24557_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11154-019-09521-z","volume":"21","author":"B Yilmaz","year":"2020","unstructured":"Yilmaz, B., Terekeci, H., Sandal, S. & Kelestimur, F. Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention. Rev. Endocr. Metab. Disord. 21 (1), 127\u2013147. https:\/\/doi.org\/10.1007\/s11154-019-09521-z (2020).","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"24557_CR55","unstructured":"Becton Dickinson and Company. BD sterifill Advance\u2122 polymer prefillable syringe for intravenous drugs [Product overview]. IndiaMART Retrieved July  (2025)."},{"key":"24557_CR56","unstructured":"SCHOTT Pharma, A. G. SCHOTT TOPPAC ready-to-use prefillable polymer syringes [Product information]  (2025)."},{"issue":"2","key":"24557_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/bjophthalmol-2019-313823","volume":"104","author":"GB Melo","year":"2020","unstructured":"Melo, G. B. et al. Release of silicone oil and the off-label use of syringes in ophthalmology. Br. J. Ophthalmol. 104 (2), 291\u2013296. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-313823 (2020).","journal-title":"Br. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24557-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:03:21Z","timestamp":1763597001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24557-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24557"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24557-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This manuscript adheres to the highest ethical standards in research and publishing. No human participants, animal subjects, or personal data were involved in the study; thus, formal ethics approval was not required. All analyses and interpretations were conducted transparently and ethically, ensuring accuracy and integrity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"40736"}}